Long-term outcome of short-course high-dose glucocorticoids for SARS: a 17-year follow-up in SARS survivors

Link to article at PubMed

Clin Infect Dis. 2020 Jul 16:ciaa992. doi: 10.1093/cid/ciaa992. Online ahead of print.


Use of high-dose glucocorticoids for coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2) is controversial because of safety concerns. We examined long-term consequences in severe acute respiratory syndrome (SARS; caused by SARS-CoV-1) survivors. Results showed that high-dose glucocorticoids greatly increased long-term risk of avascular necrosis, but not other major diseases.

PMID:32671407 | DOI:10.1093/cid/ciaa992

Leave a Reply

Your email address will not be published.